PHVS (Pharvaris N.V.) Forward P/E Multiple

Corporate company logo of Pharvaris Corp (PHVS)

Reliance on orphan drug status guarantees Pharvaris N.V. (PHVS) exclusive marketing rights. The company aims to dominate the treatment of angioedema by replacing injections with convenient deucrictibant tablets. The company's forward P/E history confirms this trajectory, with the current metric standing at 0.00. Meanwhile, the R&D center is completing a critical trial phase for breakthrough agents designed for the prevention of angioedema.

Projected Price to Earnings: Pharvaris (PHVS) for 07/04/2022 - 11/15/2026

Analytical breakdowns for Pharvaris N.V.

- current price and projected stock value:
Summary company analytics:pharvaris.com
Product sample of Pharvaris N.V.

High drug development costs leave the biotech sector vulnerable to market volatility; however, patent protection and the complexity of molecule synthesis at Pharvaris N.V. (PHVS) create significant barriers to entry for competitors. The ratio of market price to projected forward earnings allows for an assessment of the premium paid for this potential. By analyzing the company's current forward P/E ratio, an investor can determine the fairness of the valuation regarding expected earnings, where low values signal that the asset is undervalued.

Competitors of Pharvaris N.V. (PHVS)

Projected Price to Earnings ARGX (Argenx)|BNTX (BioNTech Group) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (Abivax SA)|Market Cap to Projected Earnings admabiologics.com (ADMA)|PTGX - Future Price to Earnings|Immunovant Inc (IMVT) - Projected Price to Earnings|Kiniksa Corp (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols, S.A.|Projected Price to Earnings ADPT|Forward P/E Multiple celldex.com|Future Price to Earnings Aurinia Pharma (AUPH)|BioCryst Pharmaceuticals - Price to Future Earnings Ratio|Forward P/E Multiple VERA (veratx.com)|Dianthus Pharma (DNTH) - Projected Price to Earnings Ratio|AbCellera Biologics - Forward P/E Multiple|tourmalinebio.com - Market Cap to Future Earnings Ratio|Precigen (PGEN) - Future Price to Earnings|Pharming Group - Future Price to Earnings Multiple|Future Price to Earnings Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ZBIO|Forward P/E Multiple immunome.com (IMNM)|Forward P/E Multiple GOSS (gossamerbio.com)|Market Cap to Projected Earnings KalVista Pharma (KALV)|SEPN - Future Price to Earnings|Market Cap to Projected Earnings Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Projected Price to Earnings|Price to Expected Earnings Ratio RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - Forward P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Future Price to Earnings engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Future Price to Earnings Multiple|Aerovate Therapeutics - Projected Price to Earnings|Future Price to Earnings Multiple ACRS|Kyverna Therapeutics, Inc - Forward P/E Multiple|Price to Expected Earnings Ratio TLSA|CABA: Forward P/E Multiple|Projected Price to Earnings Ventyx Bio|Future Price to Earnings Theratechnologies, Inc.|Projected Price to Earnings Ratio Avalo Therapeutics AVTX|Forward P/E Multiple ELDN|AGEN (Agenus, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Projected Price to Earnings Ratio|ATYR: Projected Price to Earnings|adagene.com (ADAG) - Projected Price to Earnings|Ikena Oncology (IMA) - Future Price to Earnings|Projected Price to Earnings Shattuck Labs, Inc.|Future Price to Earnings equilliumbio.com|Projected Price to Earnings connectbiopharm.com (CNTB)|Forward P/E Multiple IMUX|Market Cap to Projected Earnings Atara Bio|Future Price to Earnings InflaRx N.V. IFRX|X4 Pharmaceuticals - Future Price to Earnings|ACET: Projected Price to Earnings|Future Price to Earnings Multiple CELU (celularity.com)|INMB: Forward P/E Multiple|BRNS: Market Cap to Future Earnings Ratio|KZR (Kezar Life Sciences, Inc.) - Forward P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Market Cap to Projected Earnings|Forward P/E Multiple AKTX|Future Price to Earnings ENLV (Enlivex Therapeutics Ltd)|Future Price to Earnings Q32 Bio Inc. QTTB|GOVX - Projected Price to Earnings|EDSA - Future Price to Earnings|Projected Price to Earnings Ratio iBio|CARM: Forward P/E Multiple|Price to Expected Earnings Ratio XTLB (XTL Biopharmaceuticals, Ltd.)|Future Price to Earnings boltbio.com|Forward P/E Multiple HCW Biologics|Forward P/E Multiple APVO|AIM - Projected Price to Earnings Ratio|Forward P/E Multiple ADTX (Aditxt Inc.)|Market Cap to Projected Earnings GRI Bio, Inc. (GRI)|XRTX - Future Price to Earnings|reshapelifesciences.com (HIND) - Projected Price to Earnings|REVB: Forward P/E Multiple|Indaptus Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Scinai|Projected Price to Earnings Ratio CalciMedica, Inc. CALI|Future Price to Earnings Affimed NV (AFMD)|Forward P/E Multiple Allakos Inc (ALLK)|Future Price to Earnings hookipapharma.com HOOK|Forward P/E Multiple IGM Biosciences, Inc. IGMS|iTeos Pharma - Forward P/E Multiple|OCEA - Forward P/E Multiple|TCBP: Forward P/E Multiple|Third Harmonic Bio - Future Price to Earnings Multiple